Compare INLX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | IGC |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4M | 28.4M |
| IPO Year | 2013 | 2005 |
| Metric | INLX | IGC |
|---|---|---|
| Price | $5.45 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 6.7K | ★ 482.1K |
| Earning Date | 05-14-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | $11,336.00 | ★ $1,271,000.00 |
| Revenue This Year | $16.86 | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.25 | $0.24 |
| 52 Week High | $13.66 | $0.50 |
| Indicator | INLX | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | N/A |
| Support Level | $5.45 | N/A |
| Resistance Level | $7.87 | N/A |
| Average True Range (ATR) | 0.21 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.96 | 0.00 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.